United Therapeutics Wins FDA Clearance for Treprostinil-Iloprost Phase 1 Trial

MT newswire2026/10/28 14:22

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

10:22 AM EDT, 10/28/2026 (MT Newswires) -- United Therapeutics (UTHR) secured US Food and Drug Administration clearance for its investigational new drug application for Treprostinil-Iloprost SMI, clearing the way for a phase 1 trial of the inhaled combination therapy for pulmonary arterial hypertension. The study will assess the safety, tolerability and pharmacokinetics of the treprostinil-iloprost combination in healthy volunteers, the company said Wednesday in a statement. The inhaled therapy is being developed for as-needed relief of episodic symptoms in patients with PAH and is intended to help address symptom flare-ups between doses of maintenance prostacyclin therapy, the company said. If the phase 1 study is successful, United Therapeutics expects to begin a phase 2 trial in PAH patients in 2027. Price: 586.31, Change: -4.89, Percent Change: -0.83

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Well-known investor Steve Eisman has publicly criticized Anthropic, stating that the financial data in its prospectus submitted on October 26 only covers up to June, deliberately concealing the latest quarterly information. He cited data showing that Anthropic’s quarterly revenue growth rate sharply dropped from 144% in the second quarter to 45% in the third quarter, indicating a significant slowdown in growth momentum, while the cost structure simultaneously deteriorated.

华尔街见闻•2026/10/29 20:44